Landmark NHS-Galleri multi-cancer blood-test trial missed its primary goal, but found real gains in earlier-stage detection
Important context
- Not yet peer-reviewed: This record's primary source is a conference late-breaking-abstract publication (ASCO 2026 / JCO 44 LBA100), not yet independently confirmed as a full peer-reviewed manuscript as of the last_reviewed date above.
In plain English
The 30-second version
What happened?
The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV diagnoses fell 22% in the trial's second screening round and 26% in its third, the test roughly quadrupled overall cancer detection when added to standard screening, and it found more stage I/II cancers than all of the NHS's existing single-cancer screening programs combined.
Why does it matter?
A missed primary endpoint in a large, well-designed randomized trial is real, important evidence in its own right — not a story to omit or downplay — and this project's mission is to report exactly this kind of honest, mixed result, not just positive headlines; readers researching multi-cancer blood tests deserve to know this specific trial did not meet its own success bar, alongside the real gains it did find.
What does this not prove?
A missed primary endpoint means this trial did NOT establish, at a statistically significant level, that adding this test to screening reduces combined late-stage (III/IV) cancer diagnoses — the favorable secondary findings above are real but are not the same as meeting the trial's own pre-specified success criterion, and should not be reported as if the trial "succeeded." Galleri is not FDA-approved for cancer screening in the United States (it is offered there as a laboratory-developed test); this record makes no claim about its regulatory status outside the UK NHS trial context.
Keep reading for evidence stage, limitations, study details, and sources.
The NHS-Galleri trial, a large randomized controlled trial run by the UK’s National Health Service in partnership with GRAIL, enrolled roughly 142,000 asymptomatic adults aged 50-77 to test whether adding an annual Galleri multi-cancer early detection (MCED) blood test — which looks for cell-free DNA signals shared across more than 50 cancer types — to standard cancer screening could catch cancers earlier and reduce late-stage diagnoses (ClinicalTrials.gov NCT05611632; ISRCTN91431511). Full results, presented at the 2026 ASCO Annual Meeting and published in the Journal of Clinical Oncology (DOI 10.1200/JCO.2026.44.17_suppl.LBA100), reported that the trial’s PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: annual Galleri testing reduced stage IV diagnoses by 22% in the trial’s second screening round and 26% in its third round, increased the overall cancer detection rate roughly four-fold when added to standard screening, found more stage I and II cancers than all of the NHS’s existing single-cancer screening programs combined, and reduced cancer diagnosis via emergency-department presentation by 25%. Galleri is not currently FDA-approved for cancer screening in the United States; in the US it is offered as a laboratory-developed test.
Population / Applicability
Studied in: Asymptomatic adults aged 50-77 in the United Kingdom, randomized to annual Galleri multi-cancer early detection (MCED) blood testing added to standard NHS cancer screening, or standard screening alone, followed for cancer diagnoses over multiple screening rounds. (Adults)
This is a single trial in a UK population aged 50-77; results may not generalize to other age groups, populations, or healthcare-access contexts. Multi-cancer early-detection tests remain an active, evolving research area — this record should be re-checked against any later full peer-reviewed publication of these results (this record cites the ASCO 2026 late-breaking-abstract publication in JCO) before republication.
Full evidence details
- Study design
- Randomized controlled trial
- Sample size
- 142000
Funding & Conflicts
Trial run by the UK National Health Service in partnership with GRAIL, LLC, the commercial developer of the Galleri test — not independently confirmed against a primary corporate/NHS-disclosure document.
Regulatory status by jurisdiction
Country or region not specified
- Status
- Investigational
- Last verified
- 2026-08-13
Cancer-type scope for this record is not yet recorded.
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-08-13
Primary evidence supporting this story
- NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening (Journal of Clinical Oncology, 2026 ASCO Annual Meeting) (opens in a new tab) (Conference abstract) [Conference abstract] 10.1200/JCO.2026.44.17_suppl.LBA100 Primary source DOI 10.1200/JCO.2026.44.17_suppl.LBA100
NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening (Journal of Clinical Oncology, 2026 ASCO Annual Meeting). DOI 10.1200/JCO.2026.44.17_suppl.LBA100.
Additional context
- NHS-Galleri trial registry (opens in a new tab) (Clinical-trial registry) NCT05611632 NCT05611632
NHS-Galleri trial registry. NCT05611632.
Last reviewed
Landmark NHS-Galleri multi-cancer blood-test trial missed its primary goal, but found real gains in earlier-stage detection
https://cancerdiscoveries.com/discoveries/landmark-nhs-galleri-multi-cancer-blood-test-trial-missed-its-primary-goal-but-found-real-gains-in-earlier-stage-detection/
Research type: Later-stage studies in people
What This Means
The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV diagnoses fell 22% in the trial's second screening round and 26% in its third, the test roughly quadrupled overall cancer detection when added to standard screening, and it found more stage I/II cancers than all of the NHS's existing single-cancer screening programs combined.
What This Doesn't Mean
A missed primary endpoint means this trial did NOT establish, at a statistically significant level, that adding this test to screening reduces combined late-stage (III/IV) cancer diagnoses — the favorable secondary findings above are real but are not the same as meeting the trial's own pre-specified success criterion, and should not be reported as if the trial "succeeded." Galleri is not FDA-approved for cancer screening in the United States (it is offered there as a laboratory-developed test); this record makes no claim about its regulatory status outside the UK NHS trial context.
Why It Matters
A missed primary endpoint in a large, well-designed randomized trial is real, important evidence in its own right — not a story to omit or downplay — and this project's mission is to report exactly this kind of honest, mixed result, not just positive headlines; readers researching multi-cancer blood tests deserve to know this specific trial did not meet its own success bar, alongside the real gains it did find.
Important Limitations
- This record's primary source is a conference late-breaking-abstract publication (ASCO 2026 / JCO 44 LBA100), not yet independently confirmed as a full peer-reviewed manuscript as of the last_reviewed date above.
Primary sources
- NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening (Journal of Clinical Oncology, 2026 ASCO Annual Meeting) — https://doi.org/10.1200/JCO.2026.44.17_suppl.LBA100 (DOI 10.1200/JCO.2026.44.17_suppl.LBA100)
Date verified: 2026-08-13
Correction status: No correction or retraction